Janux Therapeutics price target raised to $74 from $53 at Wedbush

Wedbush analyst Robert Driscoll raised the firm’s price target on Janux Therapeutics to $74 from $53 and keeps an Outperform rating on the shares. The firm notes Janux reported Q1 results, as it continues to progress its conditionally activated T cell engagers, JANX007 and JANX008, in dose escalation trials in solid tumors. Wedbush looks forward to a clinical update on JANX007, along with expansion cohort dose selection, in the second half of 2024. The company will also provide a clinical update on JANX008 in the first half of 2025.